STAAR Surgical (STAA) Stock Price, News & Analysis

Company Overview

STAAR Surgical is a medical device company focused on ophthalmic surgery and vision correction. The company develops, manufactures and markets implantable lenses and related products designed to reduce or eliminate dependence on glasses or contact lenses.

Its principal product line is the EVO Visian Implantable Collamer Lens (ICL), a lens implanted inside the eye to correct myopia, with or without astigmatism. Unlike procedures that remove corneal tissue, ICL surgery preserves the eye’s natural lens and is designed to be removable. STAAR Surgical also offers other ophthalmic lenses and surgical products for refractive and cataract-related procedures, depending on the market.

Founded in 1982, STAAR Surgical serves ophthalmic surgeons and patients internationally through direct operations and distribution partners. Its products are marketed across the United States and numerous international markets, including countries in Europe and the Asia-Pacific region. The company is headquartered in Lake Forest, California, and its common stock trades on the Nasdaq under the symbol STAA.

Key Stats

• Today's Range: $22.09 to $22.78
• 50-Day Range: $19.08 to $26.18
• 52-Week Range: $15.59 to $35.87
• Volume: 640,036 shs
• Average Volume: 1.16 million shs
• Market Capitalization: $1.13 billion
• P/E Ratio: 321.05
• Dividend Yield: N/A
• Price Target: $28.45
• Consensus Rating: Hold

STAAR Surgical Stock Analysis - MarketRank™

STAAR Surgical scored higher than 67% of companies evaluated by MarketBeat, and ranked 246th out of 887 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.0 / 5
• Analyst Rating: Hold

Consensus Rating

STAAR Surgical has received a consensus rating of Hold. The company's average rating score is 2.08, and is based on no strong buy ratings, 4 buy ratings, 6 hold ratings, and 3 sell ratings.

Upside Potential

STAAR Surgical has a consensus price target of $28.45, representing about 26.6% upside from its current price of $22.47.

Amount of Analyst Coverage

STAAR Surgical has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 48.72%

Earnings Growth

Earnings for STAAR Surgical are expected to grow by 48.72% in the coming year, from $0.39 to $0.58 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of STAAR Surgical is 321.05, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 44.66.

Price to Earnings Ratio vs. Sector

The P/E ratio of STAAR Surgical is 321.05, which means that it is trading at a more expensive P/E ratio than the Healthcare sector average P/E ratio of about 275.67.

Price to Book Value per Share Ratio

STAAR Surgical has a P/B Ratio of 3.25. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

15.37% of the float of STAAR Surgical has been sold short.

Short Interest Ratio / Days to Cover

STAAR Surgical has a short interest ratio ("days to cover") of 4.87.

Change versus previous month

Short interest in STAAR Surgical has recently increased by 8.64%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

STAAR Surgical does not currently pay a dividend.

Dividend Growth

STAAR Surgical does not have a long track record of dividend growth.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: 0.46

News Sentiment

STAAR Surgical has a news sentiment score of 0.46. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 15 news articles for STAAR Surgical this week, compared to 6 articles on an average week.

Search Interest

Only 2 people have searched for STAA on MarketBeat in the last 30 days. This is a decrease of -60% compared to the previous 30 days.

Company Ownership

• Score: 1.4 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, STAAR Surgical insiders have not sold or bought any company stock.

Percentage Held by Insiders

39.90% of the stock of STAAR Surgical is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

96.70% of the stock of STAAR Surgical is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/12/2026
• Today: 10/04/2026
• Next Earnings (Estimated): 11/04/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Equipment
• Current Symbol: NASDAQ:STAA
• CIK: 718937
• Web: www.staar.com
• Phone: (626) 303-7902
• Fax: 626-303-2962
• Employees: 957
• Year Founded: 1982

Price Target and Rating

• Average Price Target for STAAR Surgical: $28.45
• High Price Target: $37.00
• Low Price Target: $13.00
• Potential Upside/Downside: +26.6%
• Consensus Rating: Hold
• Rating Score (0-4): 2.08
• Research Coverage: 13 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.07
• Trailing P/E Ratio: 321.05
• Forward P/E Ratio: 57.62
• P/E Growth: N/A
• Net Income: -$80.45 million
• Net Margins: 1.13%
• Pretax Margin: 5.12%
• Return on Equity: 9.05%
• Return on Assets: 6.99%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.66
• Quick Ratio: 4.03

Sales & Book Value

• Annual Sales: $239.44 million
• Price / Sales: 4.71
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $6.92 per share
• Price / Book: 3.25

Miscellaneous

• Outstanding Shares: 50,140,000
• Free Float: 30,137,000
• Market Cap: $1.13 billion
• Optionable: Optionable
• Beta: 1.17